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Abstract: Nuclear factor E2-related factor2 (Nrf2) activation is associated with both cytoprotective
effects and malignant behavior of cancer cells. This study aimed to evaluate the clinicopathological
implications of the expression of Nrf2, pNrf2, and its regulator Keap1 in human hepatocellular
carcinomas (HCCs). Tissue microarrays consisting of 285 surgically resected HCCs were
immunohistochemically stained with pNrf2, Nrf2, Keap1, stemness-related markers (keratin 19 (K19),
epithelial cell adhesion molecule (EpCAM)), carbonic anhydrase IX (CAIX), epithelial–mesenchymal
transition (EMT)-related markers (ezrin, uPAR, E-cadherin), and p53, and the results were correlated
with the clinicopathological features. pNrf2 expression was significantly associated with increased
proliferative activity, as well as EpCAM, ezrin, p53, and CAIX expression and E-cadherin loss (p < 0.05,
all). Strong cytoplasmic Nrf2 expression was associated with CAIX and ezrin expression (p < 0.05,
both). Keap1 was associated with increased proliferative activity, portal vein invasion, EMT-related
markers, and p53 expression in CAIX-negative HCCs (p < 0.05, all). Both pNrf2 and cytoplasmic
Nrf2 expression were associated with decreased overall survival (p < 0.05, both), and cytoplasmic
Nrf2 expression was an independent predictor of decreased overall survival on multivariate analysis
(hazard ratio 4.15, p < 0.001). Both pNrf2 and cytoplasmic Nrf2 expression were associated with
poor survival and aggressive behavior of HCC. In addition, Keap1 expression was also associated
with aggressive HCC behavior in CAIX-negative HCCs, suggesting that Keap1 expression should be
interpreted in the context of hypoxia status.
Keywords: Hepatocellular carcinoma; Nrf2; Keap1; prognosis
1. Introduction
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide [1]. The genomic landscape of HCC was unraveled during the past decade, with the
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most common genetic alterations being mutations in TP53, CTNNB1, and TERT promoter genes [2–4];
following the identification of distinct morphological subtypes of HCCs that partly correlate with
the molecular features, there was increasing interest in the heterogeneity of HCC in recent years [5].
This heterogeneity has important clinical implications, as understanding the morphomolecular features
of the different subtypes of HCC will lead to increased treatment options and provide background for
drug development.
Of the less frequent molecular alterations of HCC, somatic mutations in NFE2L2 and KEAP1 are
observed in 3–6% and 2–8% of HCCs, respectively [4,6]. Activating NFE2L2 mutations and inactivating
KEAP1 mutations were demonstrated to play important roles in tumor progression by preventing the
degradation of nuclear factor E2-related factor2 (Nrf2), and the Nrf2/Keap1 pathway recently attracted
attention as a potential therapeutic target for HCC [3,7,8]. Under physiological conditions, Nrf2 has
cytoprotective functions; oxidative stress induces the phosphorylation of Nrf2, and phospho-Nrf2
(pNrf2) is subsequently released from Keap1 to enter the nucleus, bind to antioxidant response
elements, and ultimately trigger the expression of cytoprotective genes [6,9,10]. However, although this
cytoprotective mechanism initially prevents carcinogenesis, the overexpression of Nrf2 in cancer cells
may result in protection of cancer cells from oxidative stress, enhancement of cancer cell proliferation
and survival, and resistance to therapy [8,11–14].
Although the prognostic and clinical implication of Nrf2 and Keap1 protein expression was
recently demonstrated in various malignant neoplasms, previous studies reported conflicting results
and there are limited data on HCC [15–22]. In this study, we evaluated the prognostic significance and
the clinicopathological features of HCCs expressing Nrf2, pNrf2, and Keap1, and we correlated the
findings with the expression status of markers associated with hypoxia (carbonic anhydrase IX; CAIX),
stemness (keratin 19; K19, epithelial cell adhesion molecule; EpCAM) and epithelial–mesenchymal
transition (EMT) (ezrin, urokinase-type plasminogen activator receptor (uPAR) and E-cadherin).
2. Results
The clinicopathological features of the 285 HCC cases are summarized in Table 1. The most
common etiology was hepatitis B virus (HBV) infection (203/285, 71.2%). Multiplicity was present in
49/285 (17.2%) cases, and 205/285 (72.0%) cases were poorly differentiated (Edmondson–Steiner grade
3 or 4). Microvascular and portal vein invasion was seen in 113/285 (39.6%) and 19/285 (6.7%) cases,
respectively. After a follow up period of 66.5 months (range, 0–163 months), 161/285 (56.5%) cases
recurred and 54/285 (18.9%) patients died.
Table 1. Summary of the clinicopathological features of hepatocellular carcinomas (n = 285).




Age at operation, median (range, years) 63 (29–87)
Etiology, n (%)
Hepatitis B virus (HBV) 202 (70.9)
Hepatitis C virus (HCV) 25 (8.8)
HBV + HCV 1 (0.3)
Alcohol 14 (4.9)
Non-alcoholic fatty liver disease 12 (4.2)
Uncertain etiology 31 (10.9)
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Table 1. Cont.
Parameters Frequency (%) or Median (Range)
Tumor size, median (range, cm) 3.2 (0.9–17)
Multiplicity present, n (%) 49 (17.2)
Edmondson–Steiner grade, n (%)
Grade I 3 (1.0)
Grade II 77 (27.0)
Grade III 171 (60.0)
Grade IV 34 (12.0)
Microvascular invasion present, n (%) 113 (39.6)
Portal vein invasion present, n (%) 19 (6.7)






Extrahepatic metastasis present, n (%) 55 (19.3)
Cirrhosis in background liver present, n (%) 152 (533.3)
Recurrence on follow-up present, n (%) 161 (56.5)
Status at last follow-up, n (%)
Alive 128 (44.9)
Deceased of disease 44 (15.4)
Deceased of other cause 10 (3.5)
Follow up loss 103 (36.2)
Overall survival, median (range, months) 66.5 (0–163)
Disease-free survival, median (range, months) 32.5 (0–163)
AJCC, American Joint Committee on Cancer.
2.1. pNrf2 Expression in HCCs and Clinicopathological Correlation
The immunohistochemical stain results and clinicopathological data are demonstrated in Figure 1
and Table 2. pNrf2 expression was observed in 73/285 (25.6%) cases, and all positive cases demonstrated
strong nuclear labeling. High pNrf2 expression was associated with significantly higher proliferative
activity (mitotic index: 17.4 ± 20.0% vs. 10.1 ± 13.4%, respectively, p < 0.001; Ki-67 labeling index
(12.9 ± 12.2 vs. 5.1 ± 7.5/10 high-power field (HPF), respectively, p < 0.001) compared with pNrf2-low
HCCs. pNrf2-high HCCs demonstrated significantly more frequent expression of EpCAM (41/73
(56.2%) vs. 84/212 (39.6%), respectively, p = 0.020), CAIX (27/72 (37.5%) vs. 48/205 (23.4%), respectively,
p = 0.030), ezrin (43/72 (59.7%) vs. 78/212 (36.8%), respectively, p = 0.001), E-cadherin loss (56/73 (76.7%)
vs. 128/212 (60.4%), respectively, p = 0.015), and p53 overexpression (26/70 (37.1%) vs. 40/195 (20.5%),
respectively, p = 0.009), compared with pNrf2-low HCCs (Figure 2). K19 expression was also slightly
more frequent in pNrf2-high HCCs; however, the difference was not statistically significant. pNrf2-high
status was significantly associated with decreased overall survival (OS) on univariate analysis (hazard
ratio (HR), 1.89: 95% confidence interval (CI), 1.04–3.46; p = 0.038) (Table 3, Figure 3). There was no
significant difference in disease-free survival (DFS) according to pNrf2 status. However, analysis of an
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independent cohort of 293 surgically resected HCCs also revealed a significant association between
pNrf2 expression and decreased OS (p = 0.001) and DFS (p = 0.029) (Figure S1).
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Figure 1. Expression of phosphorylated nuclear factor E2-related factor2 (pNrf2), Nrf2, and Keap1 in 
hepatocellular carcinomas. (A) Nuclear pNrf2 expression in 63% of tumor cells; (B) high cytoplasmic 
Nrf2 expression in tumor cells; (C) high cytoplasmic Keap1 expression in tumor cells. Original 
magnification ×200 (A), ×400 (B,C).
Figure 1. Expression of phosphorylated nuclear factor E2-related factor2 (pNrf2), Nrf2, and Keap1 in
hepatocellular carcinomas. (a) Nuclear pNrf2 expression in 63% of tumor cells; (b) high cytoplasmic Nrf2
expression in tumor cells; (c) high cytoplasmic Keap1 expression in tumor cells. Original magnification
×200 (a), ×400 (b,c).Cancers 2020, 12, x  6 of 12 
 
Figure 2. Comparison of the Ki-67 labeling indices (A,D,G), mitotic indices (B,E,H), and 
immunohistochemical characteristics (C,F,I) of hepatocellular carcinomas according to pNrf2 (A–C), 
Nrf2 (D–F), and Keap1 (G–I) expression status; * p < 0.05, ** p < 0.01; HPF: high-power field. 
2.2. Cytoplasmic Nrf2 Expression in HCCs and Clinicopathological Correlation  
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between pNrf2 and Nrf2 expression status. Nrf2-high HCCs were smaller in size compared with 
Nrf2-low HCCs (3.1 ± 1.8 cm vs. 4.4 ± 2.9 cm, respectively, p = 0.005). Cytoplasmic Nrf2 expression 
was associated with increased expression of CAIX (20/48 (41.7%) vs. 55/229 (24.0%), respectively, p = 
0.019) and Ezrin (31/48 (64.6%) vs. 90/236 (38.1%), respectively, p = 0.001) compared to Nrf2-low 
HCCs. Notably, Nrf2-high status was significantly associated with decreased OS in HCC patients on 
univariate analysis (HR, 3.33; 95% CI, 1.74–6.37; p < 0.001) (Table 3, Figure 3). 
 
Figure 3. Kaplan–Meier survival curves comparing the overall survival (A–C) and disease-free 
survival (D–F) of hepatocellular carcinomas according to pNrf2 (A,D), Nrf2 (B,E), and Keap1 (C,F) 
expression status. 
Figure 2. Comparison of the Ki-67 labeling indices (A, , ), itotic indices (B,E, ), and
immunohistochemical characteristics (C,F,I) of hepatocellular carcinomas according to pNrf2 (A–C),
Nrf2 (D–F), and Keap1 (G–I) expression status; * p < 0.05, ** p < 0.01; HPF: high-power field.
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Low pNrf2 High pNrf2 Low Nrf2 High Nrf2 Low Keap1 High Keap1
Frequency 212 (74.3) 73 (25.6) - 237 (83.2) 48 (16.8) - 124 (43.5) 161 (56.5) -
Sex (male/female) 159 (75.0)/53 (25.0) 57 (78.1)/16 (21.9) 0.638 179 (75.5)/58 (24.5) 37 (77.1)/11 (22.9) 1.000 94 (75.8)/30 (24.2) 122 (75.8)/39 (24.2) 1.000
Age ≥60 years 95 (44.8) 28 (38.4) 0.411 100 (42.2) 23 (47.9) 0.542 55 (44.7) 68 (42.2) 0.809
HBV-related etiology 150 (70.8) 53 (72.6) 0.881 167 (70.5) 36 (75.0) 0.602 86 (69.4) 117 (72.7) 0.598
Size (cm, mean ± SD) 4.2 ± 3.0 4.0 ± 2.4 0.274 4.4 ± 2.9 3.1 ± 1.8 0.005 4.4 ± 3.1 3.9 ± 2.5 0.105
Multiplicity 37 (17.5) 12 (16.4) 1.000 41 (17.3) 8 (16.7) 1.000 23 (18.5) 26 (16.1) 0.636
E–S grade III and IV 155 (73.1) 50 (68.5) 0.454 173 (73.0) 32 (66.7) 0.382 92 (74.2) 113 (70.2) 0.507
Microvascular invasion 78 (36.8) 35 (47.9) 0.098 96 (40.5) 17 (35.4) 0.628 47 (37.9) 66 (41.0) 0.627
Portal vein invasion 12 (5.7) 7 (9.6) 0.278 17 (7.2) 2 (4.2) 0.750 12 (9.7) 7 (4.3) 0.094
pT category 0.146 0.323 0.166
pT1a 31 (14.6) 6 (8.2) 33 (13.9) 4 (8.3) 18 (14.5) 19 (11.8)
pT1b 75 (35.4) 26 (35.6) 83 (35.0) 18 (37.5) 46 (37.1) 55 (34.2)
pT2 76 (35.8) 36 (49.3) 89 (37.6) 23 (47.9) 41 (33.1) 71 (44.1)
pT3 10 (4.7) 1 (1.4) 11 (4.6) 0 (0) 4 (3.2) 7 (4.3)
pT4 20 (9.4) 4 (5.5) 21 (8.9) 3 (6.3) 15 (12.1) 9 (5.6)
Recurrence 118 (55.7) 43 (58.9) 0.784 133 (56.1) 28 (58.3) 0.748 64 (51.6) 97 (60.2) 0.183
Extrahepatic metastasis 37 (17.6) 18 (24.7) 0.229 50 (21.2) 5 (9.1) 0.109 24 (19.5) 31 (19.4) 1.000
Underlying cirrhosis 108 (52.9) 44 (60.3) 0.338 125 (54.1) 27 (58.7) 0.628 65 (55.1) 87 (54.7) 1.000
K19 expression 38 (17.9) 16 (21.9) 0.490 42 (17.7) 12 (25.0) 0.233 18 (14.5) 36 (22.4) 0.127
EpCAM expression 84 (39.6) 41 (56.2) 0.020 103 (43.5) 22 (45.8) 0.873 49 (39.5) 76 (47.2) 0.229
CAIX expression 48 (23.4) 27 (37.5) 0.030 55 (24.0) 20 (41.7) 0.019 31 (25.4) 44 (28.4) 0.589
Ezrin expression 78 (36.8) 43 (59.7) 0.001 90 (38.1) 31 (64.6) 0.001 48 (38.7) 73 (45.6) 0.277
uPAR expression 58 (27.5) 26 (36.1) 0.180 70 (29.7) 14 (29.8) 1.000 29 (23.4) 55 (34.6) 0.049
E-cadherin loss 128 (60.4) 56 (76.7) 0.015 153 (64.6) 31 (64.6) 1.000 81 (65.3) 103 (64.0) 0.901
p53 overexpression 40 (20.5) 26 (37.1) 0.009 53 (24.1) 13 (28.9) 0.570 19 (16.1) 47 (32.0) 0.004
Mitotic index (/10 HPF, mean ± SD) 10.1 ± 13.4 17.4 ± 20.0 <0.001 11.9 ± 15.6 12.2 ± 16.1 0.623 10.5 ± 13.6 13.1 ± 16.9 0.056
Ki-67 labeling index (%, mean ± SD) 5.1 ± 7.5 12.9 ± 12.2 <0.001 7.2 ± 9.6 6.7 ± 9.6 0.935 5.7 ± 8.5 8.1 ± 10.2 0.035
HR: hazard ratio, CI: confidence interval, HBV: hepatitis B virus, E–S grade: Edmondson–Steiner grade, K19: keratin 19, EpCAM: epithelial cell adhesion molecule, CAIX: carbonic
anhydrase IX; uPAR: urokinase-type plasminogen activator receptor, HPF: high-power field.
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Table 3. Summary of the survival analysis results (n = 285).
Parameter
Overall Survival Disease-Free Survival
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
Parameters HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
Sex (male/female) 0.742 (0.345–1.597) 0.446 - - 0.702 (0.480–1.029) 0.069 - -
Age (≥60/<60 years) 0.960 (0.522–1.765) 0.894 - - 0.848 (0.621–1.157) 0.299 - -
Underlying HBV 1.160 (0.586–2.296) 0.671 - - 1.129 (0.801–1.590) 0.488 - -
Size (≥5cm/<5cm) 2.400 (1.315–4.382) 0.004 1.298 (0.650–2.594) 0.460 1.418 (1.012–1.988) 0.043 1.085 (0.765–1.540) 0.647
Multiplicity 2.812 (1.488–5.312) 0.001 2.156 (1.093–4.253) 0.027 1.991 (1.375–2.884) <0.001 1.487 (1.015–2.180) 0.042
E–S grade III and IV 0.951 (0.497–1.818) 0.879 - - 1.095 (0.778–1.542) 0.601 - -
Microvascular invasion 1.477 (0.813–2.682) 0.200 - - 1.308 (0.962–1.779) 0.087 - -
Portal vein invasion 3.289 (1.386–7.804) 0.007 2.435 (0.980–6.052) 0.055 1.573 (0.853–2.903) 0.147 - -
Extrahepatic metastasis 4.458 (2.445–8.130) <0.001 3.256 (1.742–6.083) <0.001 4.799 (3.411–6.753) <0.001 4.475 (3.152–6.354) <0.001
Underlying cirrhosis 1.282 (0.702–2.340) 0.419 - - 1.031 (0.758–1.404) 0.844 - -
K19 1.860 (0.957–3.614) 0.067 - - 1.209 (0.826–1.771) 0.329 - -
EpCAM 1.727 (0.951-3.137) 0.073 - - 0.889 (0.613–1.292) 0.538 - -
CAIX 1.854 (1.015–3.386) 0.044 1.402 (0.738–2.664) 0.302 1.043 (0.743–1.464) 0.809 - -
Ezrin 3.160 (1.674–5.966) <0.001 2.893 (1.527–5.483) 0.001 1.090 (0.766–1.552) 0.632 - -
uPAR 1.492 (0.812–2.743) 0.198 1.058 (0.756–1.480) 0.742
E-cadherin loss 1.037 (0.556–1.936) 0.909 0.853 (0.622–1.169) 0.323
p53 overexpression 1.777 (0.961–3.288) 0.067 - - 1.219 (0.854–1.740) 0.276 - -
Nrf2 3.329 (1.738–6.374) <0.001 4.151 (2.025–8.508) <0.001 1.315 (0.879–1.968) 0.183 - -
pNrf2 1.894 (1.037–3.458) 0.038 1.181 (0.950–3.450) 0.071 0.933 (0.661–1.317) 0.693 - -
Keap1 1.061 (0.582–1.937) 0.846 - - 1.290 (0.944–1.762) 0.109 - -
HBV: hepatitis B virus, HR: hazard ratio, CI: confidence interval, SD: standard deviation, E–S grade: Edmondson–Steiner grade, K19: keratin 19, EpCAM: epithelial cell adhesion molecule,
CAIX: carbonic anhydrase IX, uPAR: urokinase-type plasminogen activator receptor, HPF: high-power field.
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2.2. Cytoplasmic Nrf2 Expression in HCCs and Clinicopathological Correlation
Cytoplasmic Nrf2 expression was observed in 48/285 (16.8%) of HCCs. There was no correlation
between pNrf2 and Nrf2 expression status. Nrf2-high HCCs were smaller in size compared with
Nrf2-low HCCs (3.1 ± 1.8 cm vs. 4.4 ± 2.9 cm, respectively, p = 0.005). Cytoplasmic Nrf2 expression
was associated with increased expression of CAIX (20/48 (41.7%) vs. 55/229 (24.0%), respectively,
p = 0.019) and Ezrin (31/48 (64.6%) vs. 90/236 (38.1%), respectively, p = 0.001) compared to Nrf2-low
HCCs. Notably, Nrf2-high status was significantly associated with decreased OS in HCC patients on
univariate analysis (HR, 3.33; 95% CI, 1.74–6.37; p < 0.001) (Table 3, Figure 3).
2.3. Keap1 Expression in HCCs and Clinicopathological Correlation
Keap1 was expressed in the cytoplasm of 161/285 (56.5%) HCCs. Interestingly, a significant
positive correlation was observed between pNrf2 and Keap1 expression (p = 0.020). Keap1 expression
was associated with increased expression of uPAR (29/124 (23.4%) vs. 55/159 (34.6%), respectively,
p = 0.049). In addition, more frequent p53 expression (47/147 (32.0%) vs. 19/118 (16.1%), respectively,
p = 0.004) and higher proliferative activity (Ki-67 labeling index: 8.1 ± 10.2% vs. 5.7 ± 8.5%, respectively,
p = 0.035; mitotic index: 13.1 ± 16.9/10 HPF vs. 10.5 ± 13.6/10 HPF, respectively, p = 0.056) were noted
in Keap1-high HCCs, compared to Keap1-low HCCs.
The positive correlation between pNrf2 and Keap1 and the association between Keap1 and
increased proliferative activity in this study were unexpected, as Keap1 is known to suppress
Nrf2 activation and, thus, expected to have tumor-suppressive effects. We, thus, analyzed the
clinicopathological features of Keap1-positive HCCs separately in CAIX-positive (n = 75) and
CAIX-negative HCCs (n = 202). Of note, we found that Keap1 expression was associated with
increased Ki-67 labeling index (7.4 ± 10.3% vs. 4.6 ± 7.1%, respectively, p = 0.008), more frequent portal
vein invasion (1/202 (0.9%) vs. 6/75 (13.6%), respectively, p = 0.024), ezrin expression (3/91 (3.3%) vs.
13/110 (11.8%), respectively, p = 0.035), uPAR expression (15/91 (16.5%) vs. 33/110 (30.0%), respectively,
p = 0.031), and p53 expression (31/202 (29.8%) vs. 14/75 (34.1%), respectively, p = 0.009) only in
CAIX-negative HCCs, while there was no association between Keap1 status and the clinicopathological
factors in CAIX-positive HCCs (Table S1). In addition, although there were no differences in patient
survival according to Keap1 expression status, there was interestingly a tendency for decreased DFS
for Keap1-high HCCs in the CAIX-negative HCC group (p = 0.062).
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2.4. Multivariate Survival Analysis
Multivariate survival analysis was performed with clinicopathological and immunohistochemical
parameters that demonstrated statistical significance on univariate analysis, including pNrf2 and
cytoplasmic Nrf2. Other parameters associated with decreased OS on univariate analysis included
tumor multiplicity (HR, 2.81; 95% CI, 1.49–5.31; p = 0.001), tumor size (≥5 cm vs. <5 cm) (HR, 2.40; 95%
CI, 1.32–4.38; p = 0.004), portal vein invasion (HR, 3.29; 95% CI, 1.39–7.80; p = 0.007), the presence of
extrahepatic metastasis (HR, 4.46; 95% CI, 2.45–8.13; p < 0.001), and expression of CAIX (HR, 1.85; 95%
CI, 1.02–3.39; p = 0.044) and ezrin (HR, 3.16; 95% CI, 1.67–5.97; p < 0.001). Multivariate analysis revealed
cytoplasmic Nrf2 expression to be a significant independent prognostic factor for OS (HR, 4.35; 95% CI,
2.11–8.97; p < 0.001), along with tumor multiplicity (HR, 1.98; 95% CI, 1.02–3.86; p = 0.045), presence of
extrahepatic metastasis (HR, 3.75; 95% CI, 1.91–7.36; p < 0.001), and ezrin expression (HR, 2.41; 95% CI,
1.25–4.64; p = 0.009) (Table 3). As for DFS, tumor multiplicity (HR, 1.49; 95% CI, 1.02–2.18; p = 0.042)
and the presence of extrahepatic metastasis (HR, 4.48; 95% CI, 3.15–6.35; p < 0.001) were the only
significant independent predictors on multivariate analysis, and none of the immunohistochemical
markers were associated with poor DFS.
3. Discussion
In this study, we examined the expression of Nrf2, pNrf2, and Keap1 in HCCs, and we correlated
the findings with the clinicopathological parameters and expression status of stemness, hypoxia, and
EMT-related markers. The association between Nrf2 expression and poor prognosis was previously
demonstrated in various solid malignancies, including in two meta-analysis studies [18,21]; however,
the prognostic value of Nrf2/Keap1 in HCCs was only reported in two studies so far [16,22]. Zhang et al.
demonstrated an association between Nrf2 expression in HCCs and decreased survival, poor histological
differentiation, increased proliferation, and more frequent metastasis [22]. Although we observed a
significant association between strong cytoplasmic Nrf2 expression in HCC with decreased OS and
EMT-related marker expression, other clinicopathological factors such as proliferative activity were not
significantly influenced by Nrf2 expression status. The different antibodies used may partly explain
the differences; Zhang et al. described nucleocytoplasmic Nrf2 expression with predominantly nuclear
localization in their study, while Nrf2 expression in the current study was cytoplasmic. As it is the
nuclear form of Nrf2 that is recognized to be the active pro-tumorigenic form, we also examined nuclear
pNrf2 expression in HCC, and we found that pNrf2-high HCCs were associated with poor prognosis,
increased proliferative activity, and more frequent expression of markers associated with stemness,
EMT, and hypoxia. The association between pNrf2 expression and decreased survival in HCCs is
in line with a previous study by Chen et al., although we did not find the same expected positive
correlation between pNrf2 and Nrf2 expression or an inverse correlation between pNrf2 and Keap1
expression that they observed [16]. It should be noted that Chen et al. reported a larger proportion of
pNrf2-positive HCCs (50%) which could be explained by the different cut-offs; we evaluated pNrf2
using a quantitative approach and defined “pNrf2-high” HCCs (~25%) as those with strong nuclear
labeling exceeding 10%, while the former study adopted a semiquantitative approach for both pNrf2
and Keap1, counting any labeling for pNrf2 and Keap1 (in the nucleus and cytoplasm, respectively)
that was more than focal weak positive as “positive” [16]. Nevertheless, despite the differences in
interpretation methods, it is interesting that pNrf2 expression was associated with CAIX, EpCAM, K19,
and ezrin expression in this study.
A subset of HCCs that are morphologically compatible with HCC but express
immunohistochemical markers associated with stemness (e.g., K19, EpCAM, and SAL-like protein 4
(SALL4)) recently received increasing attention, as these HCCs demonstrate more aggressive behavior
compared to conventional HCCs, expression of EMT-related markers, poor prognosis, and resistance to
locoregional and systemic treatment [23–25]. HCCs expressing stemness-related markers were shown
to more frequently result in residual tumors after transarterial chemoembolization (TACE), compared
to conventional HCCs, and the residual tumors after TACE often expressed stemness-related markers
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that were co-localized with CAIX expression, thus suggesting a relationship between TACE-induced
hypoxia and stemness [26]. In this study, we found positive correlations between pNrf2 expression and
hypoxia, stemness, and EMT-related markers, suggesting a possible role for Nrf2 in the link between
tumor hypoxia, stemness, and aggressive behavior of HCC. pNrf2 may be upregulated in HCCs in
response to oxidative stress, and pNrf2 may further enhance the aggressive behavior of hypoxic HCCs;
however, functional studies would be necessary for validation.
Although Keap1 expression status was not correlated with clinicopathological factors or patient
survival, Keap1-high HCCs more frequently demonstrated p53 expression and higher proliferative
activity. In addition, a positive correlation was found between Keap1 and pNrf2 expression status.
These results are somewhat counterintuitive, as Keap1 was described to be a protein that suppresses
Nrf2 activation. Interestingly, when we examined the transcriptomics data provided by The Human
Protein Atlas (https://www.proteinatlas.org/) and UALCAN (http://ualcan.path.uab.edu/), which are
based on The Cancer Genome Atlas (TCGA) data, we found that KEAP1 messenger RNA (mRNA)
expression was in fact higher in HCCs than in non-neoplastic liver tissues, and high KEAP1 mRNA was
associated with poor prognosis in HCCs (Figure S2) [27,28]. An association between Keap1 expression
and poor prognosis was also demonstrated in endometrial cancers, and the authors postulated that the
overexpression of Keap1 may reflect Keap1 induction in the setting of oxidative stress [15]. On the other
hand, when we analyzed the Keap1 expression status separately in CAIX-positive and CAIX-negative
HCCs, we interestingly found that Keap1 expression was associated with more frequent portal vein
invasion, higher proliferative activity, frequent p53 expression, and a tendency for decreased DFS
in CAIX-negative HCCs, while Keap1 was not associated with any of the clinicopathological or
immunohistochemical factors in the CAIX-positive HCCs. Instead, Nrf2 and/or pNrf2 were the
determinants of aggressive behavior and poor survival in the setting of CAIX-positive HCCs. Thus, it is
possible that, under hypoxic stress, Nrf2 is released from Keap1 to contribute to the aggressive behavior
of HCC, while, under normoxic conditions, Keap1 is also a determinant of aggressive behavior.
In addition, the association between strong cytoplasmic Nrf2 expression and decreased OS in this
study suggests that, although the nuclear pNrf2 is the active form of Nrf2, strong overexpression of
Nrf2 in the cytoplasm is also abnormal and has prognostic implications.
There are a few limitations to this study. Firstly, although we analyzed a large number of HCCs,
this is a retrospective cohort study using formalin-fixed paraffin-embedded tissue samples and the
results are based on immunohistochemical results. As all the HCCs enrolled in this study were
surgically resected HCCs, it is possible that early well-differentiated HCCs—which are often treated by
loco-regional modalities—were less likely to be included in this study, resulting in a biased cohort
predominantly consisting of moderately to poorly differentiated HCCs. Functional studies would
need to be performed to further evaluate the functional relationships among Nrf2/Keap1, hypoxia, and
EMT. Secondly, as the majority of the HCCs in this study have an HBV-related etiology, it would be
necessary to perform a similar analysis on an independent cohort of HCCs from regions where HBV is
not as predominant.
4. Materials and Methods
4.1. Patients
A total of 285 cases of primary HCCs that were surgically resected between 2003 and 2012
at Seoul National University Bundang Hospital (Seongnam, Korea) were evaluated in this study.
Clinicopathological information was obtained from the patients’ electronic medical records, pathology
database, and a review of the archived glass slides, and it included sex, age at operation, underlying
etiology (including hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol and non-alcoholic fatty liver
disease (NAFLD)), tumor size, multiplicity, tumor differentiation (Edmonson–Steiner grade), presence
of microvascular and portal vein invasion, mitotic index, extrahepatic metastasis, and pathological T
stages according to the American Joint Committee on Cancer TNM staging system (eighth edition).
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The mitotic index was expressed as the total number of mitotic figures in 10 high-power fields (HPFs).
The clinical follow-up information, including the dates of surgery, disease recurrence, death, and most
recent follow-up, was retrieved from the electronic medical records. Overall survival (OS) was defined
as the number of months between surgery and patient death, and disease-free survival (DFS) was
defined as the number of months between surgery and disease recurrence (local recurrence and/or
distant metastasis). In addition, a separate independent tissue microarray cohort of 293 resected HCCs
from Seoul National University Hospital was evaluated to further examine the prognostic significance
of pNrf2 expression. This study was approved by the Institutional Review Board of Seoul National
University Hospital and Seoul National University Bundang Hospital (joint IRB# H-1808-073-965), and
patient consent was waived due to the retrospective nature of this study.
4.2. Tissue Samples and Immunohistochemistry
Tissue microarrays with tissue cores measuring 2 mm in diameter were constructed from
formalin-fixed paraffin-embedded HCC tissue, and they were arranged in recipient tissue microarray
blocks using a trephine apparatus (Superbiochips Laboratories, Seoul, Korea). Immunohistochemistry
was performed on 4-µm-thick tissue sections using antibodies for pNrf2, Nrf2, Keap1, K19, EpCAM,
E-cadherin, CAIX, p53, and Ki-67, using an automated platform (Ventana BenchMark GX, Ventana
Medical Systems, Oro Valley, AZ, USA). Immunohistochemical staining for ezrin and uPAR was
performed manually, with antigen retrieval using the citrate buffer (pH 6.0) and the Envision Kit (Dako,
Glostrup, Denmark). Detailed information on the antibodies is summarized in Table 4.
Table 4. Summary of the antibodies used in this study.
Antibody Description Source Dilution Method




















Ezrin Mouse monoclonal (3C12)
Abcam
1:100 Manual (pH 6.0)
(Cambridge, UK)
uPAR Mouse monoclonal (R-4)
Abcam
1:40 Manual (pH 6.0)
(Cambridge, UK)
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For Nrf2 and Keap1, the intensity of cytoplasmic expression in the tumor cells was recorded
as 0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong). Nrf2 expression was cytoplasmic, and
strong positive (3+) staining was designated as “Nrf2-high” (overexpression). “Keap1-high” was
defined as moderate to strong cytoplasmic staining in the tumor cells, and the staining intensity
was similar to or more intense than that seen in non-neoplastic hepatocytes, cholangiocytes, and
stromal cells. pNrf2 staining was evaluated in a quantitative manner, using the ImageJ software
(National Institutes of Health, Bethesda, MD, USA); the percentage of nuclear pNrf2 labeling was
calculated by dividing the number of positively stained tumor cell nuclei by the total number of tumor
cell nuclei, in an HPF (400×magnification). “pNrf2-high” was defined as pNrf2 labeling in ≥10% of
tumor cells. K19, EpCAM, CAIX, ezrin, and uPAR expression was designated positive when there was
cytoplasmic (K19, CAIX, ezrin) or membranous (EpCAM and uPAR) expression in ≥5% of the tumor
cells. Loss of E-cadherin expression was defined as complete absence of membranous E-cadherin
expression in the tumor cells. p53 expression was defined as positive when strong nuclear labeling
was present in more than 10% HCC cells. Two pathologists (K.L. and H.K.) independently evaluated
the immunohistochemical stains and reached an agreement using a multihead microscope when there
were discrepancies in the interpretation results.
4.3. Statistical Analysis
All data were analyzed using IBM SPSS statistics software version 25.0 (SPSS Inc., Chicago, IL,
USA) and GraphPad Prism software version 7.0 (San Diego, CA, USA), and a p-value <0.05 was
considered statistically significant. The associations between the immunohistochemical stain results
and clinicopathological parameters were assessed using the χ2 test, Fisher exact test, and Student’s t-test,
as deemed appropriate. OS and DFS were analyzed using the Kaplan–Meier method and the log-rank
test. Multivariate analysis using the Cox regression model was performed for clinicopathological and
immunohistochemical parameters with p < 0.05 on univariate analysis.
5. Conclusions
In summary, we demonstrate that pNrf2 expression in HCC was associated with increased
proliferative activity, decreased survival, and more frequent expression of hypoxia, stemness,
and EMT-related markers, suggesting a possible role for pNrf2 as a marker of aggressive behavior
and poor prognosis in HCC. In addition, contrary to previous knowledge, strong cytoplasmic Nrf2
expression was also an independent predictor of decreased survival in HCC, and Keap1 expression was
associated with aggressive HCC behavior in CAIX-negative tumors, suggesting that Keap1 expression
in HCCs should be interpreted in the context of the metabolic status. Further prognostic studies in
independent cohorts and functional studies would be required to validate the current findings.
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in HCCs compared to non-neoplastic liver tissue (A) and decreased overall survival in KEAP1-high HCCs (B) in
the LIHC cohort from The Cancer Genome Atlas (graphs generated from UALCAN, http://ualcan.path.uab.edu/);
Table S1. Clinicopathologic features according to Keap1 expression status in CAIX-positive and CAIX-negative
hepatocellular carcinomas.
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